Unexpected roles for PCSK9 in lipid metabolism

被引:34
|
作者
Soutar, Anne K. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Lipoprot Grp, Fac Med, London W1N 0NN, England
基金
英国医学研究理事会;
关键词
apolipoprotein B; LDL-receptor pathway; PCSK9; triglyceride secretion; AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; CORONARY-HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC CAUSES; PLASMA PCSK9; APO-B; SECRETION; LIVER; MICE; LDL;
D O I
10.1097/MOL.0b013e32834622b5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review To consider the evidence that PCSK9 has effects on lipoprotein metabolism that are in addition to its role in promoting the degradation of the LDL receptor. Recent findings Transgenic mice expressing human PCSK9 under physiological control have recently been described. As well as the expected effects on LDL-receptor protein levels in the liver, mice expressing the gain-of-function mutant D374Y secrete more triglyceride than control mice or mice expressing wild-type PCSK9, supporting earlier suggestions that apoB synthesis is increased in hepatocytes expressing D374Y PCSK9 and that patients heterozygous for PCSK9 mutations have increased apoB synthesis. No increase in triglyceride secretion was observed in LDLR-/- mice, suggesting that the effect of PCSK9 on triglyceride secretion is to some extent independent of the LDL receptor. Other recent studies have shown an association between serum PCSK9 concentration and serum triglyceride, but care has to be taken in interpretation of these results as it has also been shown that the level of PCSK9 in human serum shows strong diurnal variation. Summary Understanding the physiology of PCSK9 is important because this protein has become a major new target for lipid lowering therapy.
引用
收藏
页码:192 / 196
页数:5
相关论文
共 50 条
  • [1] Role of PCSK9 in lipid metabolism and atherosclerosis
    Lin, Xiao-Long
    Xiao, Le-Le
    Tang, Zhi-Han
    Jiang, Zhi-Sheng
    Liu, Mi-Hua
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 36 - 44
  • [2] PCSK9 targets important for lipid metabolism
    Schulz R.
    Schlüter K.-D.
    Clinical Research in Cardiology Supplements, 2017, 12 (Suppl 1) : 2 - 11
  • [3] Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria
    Hummelgaard, Sandra
    Kresse, Jean-Claude
    Jensen, Michael Schou
    Glerup, Simon
    Weyer, Kathrin
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2025,
  • [4] Unraveling Estrogen and PCSK9's Roles in Lipid Metabolism Disorders among Ovariectomized Mice
    Yang, Jie
    Xu, Miaomiao
    Wang, Zun
    He, Man
    Zhang, Gao
    Jin, Lei
    Zhao, Rongqian
    Pan, Yiran
    Tong, Jiyu
    Nie, Li
    REPRODUCTIVE SCIENCES, 2025, 32 (02) : 316 - 325
  • [5] PCSK9 in metabolism and diseases
    Ajoolabady, Amir
    Pratico, Domenico
    Mazidi, Mohsen
    Davies, Ian G.
    Lip, Gregory Y. H.
    Seidah, Nabil
    Libby, Peter
    Kroemer, Guido
    Ren, Jun
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
  • [6] Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis
    Cui, Jun
    Qiu, Yuxiang
    Kang, Ningsu
    Lu, Jianxun
    Zheng, Lu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12): : 1430 - 1437
  • [7] PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
    Alannan, Malak
    Seidah, Nabil G. G.
    Merched, Aksam J. J.
    CELLS, 2022, 11 (24)
  • [8] Lipid lowering with PCSK9 inhibitors
    Razvan T. Dadu
    Christie M. Ballantyne
    Nature Reviews Cardiology, 2014, 11 : 563 - 575
  • [9] Lipid lowering with PCSK9 inhibitors
    Dadu, Razvan T.
    Ballantyne, Christie M.
    NATURE REVIEWS CARDIOLOGY, 2014, 11 (10) : 563 - 575
  • [10] PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
    Andreadou, Ioanna
    Tsoumani, Maria
    Vilahur, Gemma
    Ikonomidis, Ignatios
    Badimon, Lina
    Varga, Zoltan V.
    Ferdinandy, Peter
    Schulz, Rainer
    FRONTIERS IN PHYSIOLOGY, 2020, 11